This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Paediatric Investigation Plan: Requirements, process, and comparison with US PSP
Published on: Jun 25th, 2015
A Paediatric Investigation Plan is on the critical path to obtain market approval in Europe, even if the condition does not occur in children. A PIP must be agreed with regulators before submitting a Marketing Authorization Application. If PIP requirements can be waived or deferred under specific circumstances, the negotiation process takes up to a year.
In the US, a Paediatric Study Plan must be submitted not later than 60 after the end-of-phase 2 meeting. Such a requirement can also be waived or deferred. How does the PSP process compares with the EU PIP, and can both be coordinated?
The webinar covered:
- Understanding of PIP requirements
- Obstacles and approaches to successful PIP submission
- Regulatory assessors’ perspective
- PIP implications and timelines
- Comparison with US PSP
Access the full webinar replay now
Fill in the form to download the content